# ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

> **NCT06714357** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 130 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** irinotecan
- **DRUG:** panitumumab
- **DRUG:** Valproic Acid (VPA)

## Key facts

- **NCT ID:** NCT06714357
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2026-12-20
- **Final completion:** 2027-06-20
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06714357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06714357, "ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06714357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*